Snowden Capital Advisors LLC Has $3.91 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Snowden Capital Advisors LLC decreased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 34.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,058 shares of the biopharmaceutical company’s stock after selling 35,723 shares during the period. Snowden Capital Advisors LLC’s holdings in Bristol-Myers Squibb were worth $3,906,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BMY. Accurate Wealth Management LLC lifted its position in Bristol-Myers Squibb by 47.0% during the 4th quarter. Accurate Wealth Management LLC now owns 6,140 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 1,963 shares during the period. Park Avenue Securities LLC lifted its position in Bristol-Myers Squibb by 32.6% during the 4th quarter. Park Avenue Securities LLC now owns 56,806 shares of the biopharmaceutical company’s stock valued at $3,213,000 after purchasing an additional 13,952 shares during the period. Burney Co. lifted its position in Bristol-Myers Squibb by 4.2% during the 4th quarter. Burney Co. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 516 shares during the period. Pinnacle Bancorp Inc. lifted its position in Bristol-Myers Squibb by 23.3% during the 4th quarter. Pinnacle Bancorp Inc. now owns 3,176 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 600 shares during the period. Finally, Carnegie Investment Counsel lifted its position in Bristol-Myers Squibb by 3.7% during the 4th quarter. Carnegie Investment Counsel now owns 33,435 shares of the biopharmaceutical company’s stock valued at $1,891,000 after purchasing an additional 1,193 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Samit Hirawat bought 4,250 shares of the business’s stock in a transaction on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of analyst reports. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. UBS Group lowered their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Cantor Fitzgerald reissued a “neutral” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Finally, Argus raised Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Stock Up 2.1%

Shares of NYSE:BMY opened at $46.77 on Friday. The company has a market capitalization of $95.18 billion, a PE ratio of -10.58, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The business has a fifty day moving average price of $53.05 and a two-hundred day moving average price of $55.97. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($4.40) EPS. Analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a $0.62 dividend. The ex-dividend date was Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 5.30%. Bristol-Myers Squibb’s dividend payout ratio is currently 92.88%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.